Prospective validation of the prognostic relevance of CD34+CD38 AML stem cell frequency in the HOVON-SAKK132 trial

Lok Lam Ngai, Diana Hanekamp, Fleur Janssen, Jannemieke Carbaat-Ham, Maaike A.M.A. Hofland, Mona M.H.E. Fayed, Angèle Kelder, Laura Oudshoorn-van Marsbergen, Willemijn J. Scholten, Alexander N. Snel, Costa Bachas, Jesse M. Tettero, Dimitri A. Breems, Thomas Fischer, Bjørn T. Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Arjan A. van de Loosdrecht, Johan A. Maertens, Markus G. ManzThomas Pabst, Jakob R. Passweg, Kimmo Porkka, Peter J.M. Valk, Patrycja Gradowska, Bob Löwenberg, David C. de Leeuw, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
26 Downloads (Pure)
Original languageEnglish
Pages (from-to)2657-2661
Number of pages5
JournalBlood
Volume141
Issue number21
DOIs
Publication statusPublished - 25 May 2023

Bibliographical note

Funding Information:
This research was funded by the Dutch Cancer Society grant number ALPE-2013-6371.

Cite this